fashion -WSS

fashion

author：explore 2025-09-29 17:03:06 - browse：1

Adam's take main illustration — Molly Ferguson/STAT

The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.

Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.

The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Trump surgeon general acknowledges mistakes during Covid

knowledge

WSS

This gene therapy has record $4.25 million price. It's saved children.

Medicare Advantage insurers pressure Biden for bigger payments

A rare thyroid diagnosis led to unexpected, all

Pregnancy ages women, but effects reverse after delivery

Bring on the sabbaticals for nurses

Stem cell treatment guidelines are released by FDA

leisure time

fashion

Wikipedia

Peter Hotez and the public health issue of online harassment

Covid hospitalizations on the rise, Humana says

Drug repurposing or repositioning? The language matters

This gene therapy has record $4.25 million price. It's saved children.

As demand for Covid shots wanes, Moderna seeks its next success

Diabetes management: Digital health tools fall short, study says

Heart attack and stroke risk calculators need revising

This gene therapy has record $4.25 million price. It's saved children.

At least 13 dead in Texas as scorching temps continue

Medicare Advantage insurers pressure Biden for bigger payments

explore

Testing GLP

ALS advocates say criticism of new drugs misses bigger picture

Steward Health Care expansion into Malta flopped

Biotech investment managers search for lucrative opportunities

Covid hospitalizations on the rise, Humana says

CRISPR technology availability, affordability needs to be expanded

focus

knowledge

hotspot

entertainment